Crinetics Pharmaceuticals (CRNX) Proxy filing summary

Executive summary

• Shareholders are asked to vote on a merger agreement where the company will be acquired by Vertex Pharmaceuticals for $85.00 per share in cash, resulting in the company becoming a wholly owned subsidiary and its shares being delisted from Nasdaq.

• The board unanimously recommends approval of the merger, citing a significant premium to recent trading prices and the certainty of value for shareholders.

• The merger is expected to close in the third quarter of 2026, subject to regulatory and shareholder approvals.

• If the merger is not completed, the company will remain independent, and a termination fee of $350,474,425 may be payable under certain circumstances.

Voting matters and shareholder proposals

• Shareholders will vote on three proposals: (1) adoption of the merger agreement, (2) a non-binding advisory vote on compensation for named executive officers related to the merger, and (3) adjournment of the special meeting if more votes are needed.

• Approval of the merger requires a majority of outstanding shares; the compensation and adjournment proposals require a majority of votes cast.

• Failure to vote or instruct a broker will have the same effect as a vote against the merger proposal.

Board of directors and corporate governance

• The board conducted a thorough review of strategic alternatives, engaged financial and legal advisors, and negotiated with multiple parties before recommending the Vertex transaction.

• The board considered the fairness opinions of J.P. Morgan and Leerink Partners, both of which concluded the merger consideration is fair from a financial point of view.

• Directors and officers are entitled to indemnification and continued D&O insurance for six years post-merger.